Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
LAWRENCEVILLE, N.J., May 08, 2018 -- Celsion Corporation (NASDAQ: CLSN) announced today that Michael H. Tardugno, Chairman, President and Chief Executive Officer of Celsion, will present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference being held on May 8 – 9, 2018 at Reed Smith, LLP in New York City. Mr. Tardugno’s presentation details are as follows:
Corporate Presentation:
- Date and Time: Tuesday, May 8, 2017 at 9:30 a.m. – 9:50 a.m. EDT
- Location: Room A/B
Slide Presentation Available on Celsion’s Website
To view Mr. Tardugno’s slide presentation from the event, please visit Celsion’s corporate website at http://investor.celsion.com/financial-events .
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in development for other cancer indications. The Company’s product pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: http://www.celsion.com. (CLSN-FIN).
Celsion Investor Contact Jeffrey W. Church Sr. Vice President and CFO 609-482-2455 [email protected]
